Company Profile For Regen Therapeutics PLC

ReGen Therapeutics Plc (ReGen) is a United Kingdom-based company. The principal activity of the Company is the development of healthcare products both nutraceutical and ethical products. During the year ended December 31, 2008, the Company operated in two business segments: the commercial development and sale of Colostrinin as a nutraceutical product, and the provision of clinical research services. In addition, the Company is engaged in progressing Colostrinin and its constituent peptides in terms of their development on the pharmaceutical front together with continuing to develop new formulations of zolpidem as a form of a clinically significant benefit. During 2008, the Company discontinued the provision of clinical research services.

BRIEF: For the fiscal year ended 31 December 2008, ReGen Therapeutics Plc's revenues increased 44% to £92K. Net loss from continuing operations decreased 41% to £1.4M. Revenues reflect an increase in income from Nutraceutical & pharmaceutical development division. Lower loss was partially offset by a decrease in finance income. ReGen Therapeutics Plc is principally engaged in the drug development and ancillary services.